|
|
Resende,C.B.; Rezende,B.M.; Bernardes,P.T.T.; Teixeira,G.M.; Teixeira,M.M.; Pinho,V.; Bittencourt,H.. |
Acute graft-versus-host disease (aGVHD) and cytomegalovirus reactivation are important complications after allogeneic stem cell transplantation (alloHSCT). Here, we evaluated the impact of treatment with alemtuzumab on the occurrence of aGVHD, cytomegalovirus reactivation and survival after alloHSCT. This was a prospective cohort study conducted at the allo-HSCT unit of Hospital das Clínicas, Universidade Federal de Minas Gerais, Brazil, from January 2009 to December 2011. Fifty-seven patients who underwent alloHSCT were included. Forty-five (79%) patients had a malignant disease. Alemtuzumab was administered before the conditioning regimen at a dose of 1 mg/kg in children and 30 mg/day for 2 days in adults or children weighing more than 40 kg (a total... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hematopoietic stem cell transplantation; Alemtuzumab; Graft-versus-host disease; Cytomegalovirus. |
Ano: 2017 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000200705 |
| |